Osteoarthritis

PolarityTE Announces Richard Hague, Formerly from Sanofi, Genzyme and Recently Anika Therapeutics as Chief Operating Officer

Retrieved on: 
Friday, March 29, 2019
Companies, Sanofi, CAC 40, Genzyme, Biotechnology companies, Osteoarthritis, Life sciences

Mr. Hague joins PolarityTE from Anika Therapeutics where he served as Chief Commercial Officer, overseeing the launch of a novel device-drug combination injection therapy for osteoarthritis.

Key Points: 
  • Mr. Hague joins PolarityTE from Anika Therapeutics where he served as Chief Commercial Officer, overseeing the launch of a novel device-drug combination injection therapy for osteoarthritis.
  • While at TEI Medical, he built a commercial team for a bioengineered dermal scaffold used in the treatment of wounds.
  • Mr. Hague spent a significant portion of his career at Genzyme and later Sanofi (post Sanofi's acquisition of Genzyme).
  • POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, and WELCOME TO THE SHIFT are trademarks or registered trademarks of PolarityTE, Inc.

Wait times for joint replacements and cataract surgery growing in much of Canada

Retrieved on: 
Thursday, March 28, 2019
Medical specialties, Surgery, Medicine, Prosthetics, RTT, Skeletal disorders, Arthritis, Osteoarthritis, Knee replacement, Joint replacement, Hip replacement, Orthopedic surgery

Dr. Eric Bohm, Orthopedic Surgeon and Canadian Joint Replacement Registry Advisory Committee Chair

Key Points: 
  • Dr. Eric Bohm, Orthopedic Surgeon and Canadian Joint Replacement Registry Advisory Committee Chair
    Wait times for hip replacement, knee replacement and cataract surgeries continue to vary depending on where patients live.
  • "Reducing wait times is a complex challenge and we see from the data that increasing the number of surgeries performed won't necessarily mean patients will experience shorter wait times.
  • For example, Canada's growing and aging population, as well as increases in conditions such as osteoarthritis and obesity, have contributed to a growing demand for these joint replacement procedures."
  • We protect the privacy of Canadians by ensuring the confidentiality and integrity of the health care information we provide.

New Study Shows Daily Use Of Antioxidant Pycnogenol® Improves Osteoarthritis Symptoms, Reduces Need for NSAID Painkillers

Retrieved on: 
Tuesday, March 26, 2019
Skeletal disorders, RTT, Medical specialties, Medicine, Health, Arthritis, Osteoarthritis, Aging-associated diseases, Rheumatology

A peer-reviewed and published study shows the efficacy of the super-antioxidant Pycnogenol, in the form of a topical patch, for relieving joint inflammation and discomfort associated with osteoarthritis.

Key Points: 
  • A peer-reviewed and published study shows the efficacy of the super-antioxidant Pycnogenol, in the form of a topical patch, for relieving joint inflammation and discomfort associated with osteoarthritis.
  • Participants in the independent study applied a topical patch containing 110mg of Pycnogenol in the area of pain twice daily over the course of three weeks.
  • Pycnogenol is a powerful antioxidant shown in nearly five decades of research to reduce inflammation in patients experiencing osteoarthritis symptoms.
  • Previous research published in the Journal of Phytotherapy Research in 2008 also indicates that supplementing daily with Pycnogenol reduces overall knee osteoarthritis symptoms by 20.9 percent.

Synerkine Pharma Raises EUR3.3 Million in Series A Financing

Retrieved on: 
Monday, March 25, 2019
Health, Biotechnology, Pharmaceutical, Pain, Perception, Nociception, RTT, Arthritis, Osteoarthritis, Neuropathic pain, Chronic pain

Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the companys founders.

Key Points: 
  • Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the companys founders.
  • Hans Preusting, co-founder and CEO of Synerkine Pharma, said: We are delighted with the closing of the Series A financing.
  • The proceeds will allow us to deliver a pre-clinical proof of concept in osteoarthritis and neuropathic pain over the next two years.
  • Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain.

AlzeCure Initiates New Drug Project Within Pain

Retrieved on: 
Wednesday, March 20, 2019
Pain, Perception, Medicine, RTT, Skeletal disorders, Acute pain, Nociception, Osteoarthritis, Tropomyosin receptor kinase A, Low back pain, Arthritis

The new project, which is in early preclinical phase, focuses on the treatment of pain through a target mechanism that has both strong preclinical and clinical validation.

Key Points: 
  • The new project, which is in early preclinical phase, focuses on the treatment of pain through a target mechanism that has both strong preclinical and clinical validation.
  • The goal of the new project is to develop a small-molecule TrkA-negative allosteric modulator that can reduce movement-induced and spontaneous pain in patients with painful osteoarthritis.
  • "The team at AlzeCure have many years of experience in research in the neurology and pain area.
  • In the promising drug project TrkA-NAM, we have benefited from our knowledge within the underlying biology of the NeuroRestore platform to develop new small molecule compounds that induce pain relief in a number of difficult pain conditions, such as osteoarthritis and chronic lower back pain", said Johan Sandin, CEO of AlzeCure.

AlzeCure Initiates New Drug Project Within Pain

Retrieved on: 
Wednesday, March 20, 2019
Pain, Perception, Medicine, RTT, Skeletal disorders, Acute pain, Nociception, Osteoarthritis, Tropomyosin receptor kinase A, Low back pain, Arthritis

The new project, which is in early preclinical phase, focuses on the treatment of pain through a target mechanism that has both strong preclinical and clinical validation.

Key Points: 
  • The new project, which is in early preclinical phase, focuses on the treatment of pain through a target mechanism that has both strong preclinical and clinical validation.
  • The goal of the new project is to develop a small-molecule TrkA-negative allosteric modulator that can reduce movement-induced and spontaneous pain in patients with painful osteoarthritis.
  • "The team at AlzeCure have many years of experience in research in the neurology and pain area.
  • In the promising drug project TrkA-NAM, we have benefited from our knowledge within the underlying biology of the NeuroRestore platform to develop new small molecule compounds that induce pain relief in a number of difficult pain conditions, such as osteoarthritis and chronic lower back pain", said Johan Sandin, CEO of AlzeCure.

In the report the orthopedic braces and supports market, the market is expected to reach US$ $ 5,429.3 Mn in 2025 from US$ 3,631.2 in 2017

Retrieved on: 
Monday, March 18, 2019
Medical specialties, Medicine, Musculoskeletal system, Skeletal disorders, RTT, Orthopedics, Rheumatology, Arthritis, Osteoarthritis, Orthotics, Orthopedic surgery, Dental braces

NEW YORK, March 18, 2019 /PRNewswire/ -- In the report the orthopedic braces and supports market, the market is expected to reach US$ $ 5,429.3 Mn in 2025 from US$ 3,631.2 in 2017.

Key Points: 
  • NEW YORK, March 18, 2019 /PRNewswire/ -- In the report the orthopedic braces and supports market, the market is expected to reach US$ $ 5,429.3 Mn in 2025 from US$ 3,631.2 in 2017.
  • The market of knee segment has the highest market share in 2017, contributing to orthopedic braces and supports market is of 41.5% and is expected to retain its dominance during the forecast period from 2018 to 2025.
  • The application segment of the orthopedic braces and supports market includes ligament injury, osteoarthritis, preventive care, cold bracing and others.
  • The application segment for the orthopedic braces and supports market was valued at US$ 3,631.2 Mn in 2017 and is estimated to reach US$ 5,429.3 Mn by 2025.

Worldwide Osteoarthritis Treatment Market Analysis, 2019-2024 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2019
Health, Pharmaceutical, Medical specialties, Skeletal disorders, RTT, Medicine, Health, Arthritis, Rheumatology, Osteoarthritis, Aging-associated diseases, Surgery

The osteoarthritis treatment market is expected to register a CAGR of nearly 4.2% during the forecast period, 2019-2024.

Key Points: 
  • The osteoarthritis treatment market is expected to register a CAGR of nearly 4.2% during the forecast period, 2019-2024.
  • The growth of the global osteoarthritis treatment market is due to the rising geriatric population, increasing incidence of osteoarthritis disorders, and rising demand for minimally invasive surgical procedures.
  • Hence, ongoing research and rising government support help in creating new opportunities for the growth of the osteoarthritis treatment market.
  • The availability of better treatment options, high awareness among people, government reimbursement policies, and the willingness to take up treatment are expected to add up to the growth of the osteoarthritis treatment market in the region.

Osteoarthritis Treatment to 2024: Global Market to be Dominated by Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Retrieved on: 
Friday, March 15, 2019
Skeletal disorders, Medical specialties, Medicine, RTT, Arthritis, Health, Rheumatology, Osteoarthritis, Aging-associated diseases, Surgery, Knee arthritis

The osteoarthritis treatment market is expected to register a CAGR of nearly 4.2% during the forecast period, 2019-2024.

Key Points: 
  • The osteoarthritis treatment market is expected to register a CAGR of nearly 4.2% during the forecast period, 2019-2024.
  • The growth of the global osteoarthritis treatment market is due to the rising geriatric population, increasing incidence of osteoarthritis disorders, and rising demand for minimally invasive surgical procedures.
  • The global increase in geriatric population leads to higher incidence of osteoarthritis (OA) among the aged population.
  • Hence, ongoing research and rising government support help in creating new opportunities for the growth of the osteoarthritis treatment market.

Constance R. Chu, MD, receives Kappa Delta Elizabeth Winston Lanier Award for breakthrough MRI to help prevent osteoarthritis

Retrieved on: 
Thursday, March 14, 2019
Medical specialties, Skeletal disorders, Medicine, RTT, Health, Arthritis, Aging-associated diseases, Rheumatology, Osteoarthritis, Cartilage, American Academy of Orthopaedic Surgeons

LAS VEGAS, March 14, 2019 /PRNewswire/ -- Constance R. Chu, MD, was presented with the Kappa Delta Elizabeth Winston Lanier Award at the 2019 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) for her research in advanced imaging technology to help prevent osteoarthritis (OA).

Key Points: 
  • LAS VEGAS, March 14, 2019 /PRNewswire/ -- Constance R. Chu, MD, was presented with the Kappa Delta Elizabeth Winston Lanier Award at the 2019 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) for her research in advanced imaging technology to help prevent osteoarthritis (OA).
  • During this time, Dr. Chu and her team studied four imaging techniques to identify cartilage and joint abnormalities following joint injury.
  • Dr. Chu's goal was to identify pre-OA joints to determine if the damage could be reversed before the onset of OA.
  • This is Dr. Chu's second Kappa Delta Award, having received the Young Investigator Award in 2007.